Friday, July 10, 2026

Drug profile · INN

valproate sodium

valproate sodium (VALPROATE SODIUM) is a succinate semialdehyde dehydrogenase inhibitor. Route of administration: injection. Current US regulatory status: approved.

FDA: approved
US status approved
Patents linked 0
Pipeline programs 1
News articles 0
Drug details — valproate sodium
US status
approved
Class
Route
INJECTION
Patents
0
Programs
1
Data quality
0.84

Quick answer

valproate sodium (VALPROATE SODIUM) is a succinate semialdehyde dehydrogenase inhibitor. Route of administration: injection. Current US regulatory status: approved.

Key facts

INN valproate sodium
Brand VALPROATE SODIUM
Mechanism Succinate semialdehyde dehydrogenase inhibitor
Target Succinate-semialdehyde dehydrogenase, mitochondrial
Route INJECTION
Formulation INJECTABLE

Mechanism of action

Succinate semialdehyde dehydrogenase inhibitor

Primary target: Succinate-semialdehyde dehydrogenase, mitochondrial

Approval history

Authority Status Date
FDA approved

Pipeline programs

  1. Valproate Phase 2 · BRIGHT MINDS BIOSCIENCES · Bipolar Disorder

Related & competitor drugs

  1. divalproex sodium Succinate semialdehyde dehydrogenase inhibitor
  2. valproic acid Succinate semialdehyde dehydrogenase inhibitor
  3. valproate Succinate semialdehyde dehydrogenase inhibitor

Frequently asked questions

What is valproate sodium?

valproate sodium (VALPROATE SODIUM) is a succinate semialdehyde dehydrogenase inhibitor. Route of administration: injection. Current US regulatory status: approved.

What is the brand name for valproate sodium?

VALPROATE SODIUM is a marketed brand name for valproate sodium. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of valproate sodium?

valproate sodium has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.